Summary of Interim Report January - March 2021, Dicot AB

Press release: Uppsala, May 17, 2021. A summary of the Interim report January - March 2021, for Dicot AB (publ) is now avalible on the company webbsite 

January - March 2021

  • Net sales amounts to KSEK 37 (0)
  • Earnings for the period amounts to KSEK -8,468 (-6,572).
  • Earnings per share -0.19 (-0.40) SEK

Statement from the CEO

The first quarter of 2021 is to be regarded as Dicot's starting point for the industrialization phase.

THERE ARE SEVERAL FACTORS that determine whether you will achieve success when a business enters such a phase. One is, of course, to have access to the right people and competence.

FOR A COMPANY OF OUR SIZE, where there is no room to hire all expert roles, partners are crucial. It is gratifying that the collaborations we have are so positive and lead to such good results. Pelvipharm, which we often mention, is one example. In constant dialogue with researchers in Paris, we have during the quarter started promising studies on rats that have proven reduced erectile ability.

OUR CLOSEST PARTNER geographically is Ardena in Södertälje, which is a certified CDMO (Contract Development and Manufacturing Organization). In March, we started producing the batch of our extract that will be used up to and including clinical studies, together with them.

FOR SOME TIME NOW, we have also been collaborating with Professor Ola Spjuth at Uppsala University. He uses so-called Cell Painting technology, which involves morphological analysis and comparison with other substances. This can give us valuable information about the mechanism of action of LIB-01.

WITHIN THE COMPANY, we are preparing for the industrialization phase. During the quarter, we therefore began the recruitment of a vice president who will also hold the position as COO and thus be responsible for drug development and manufacturing. The person we are looking for will lead the expansion of Dicot's organization.

LAST BUT NOT LEAST, our board and the expertise it possesses is a great asset. Therefore, it is satisfying that we were able to elect Eva Sjökvist Saers as the new Chairman of the Board in early February. She brings great energy and commitment alongside with her strong merits from the life science sector.

ALL SHAREHOLDERS who have chosen to invest in Dicot are also an important success factor. A sign that there is good confidence in us, I would say, is that the exercise of warrants of the TO2 series conducted in March, ended in a utilization rate of 97%.

I WANT TO SUM UP by thanking all stakeholders who in various ways contribute to bringing Dicot closer to our goals and visions. Thank you, employees, partners, board, shareholders, and new investors, for the collaboration and the trust. 2021 has started in a very satisfactory way. I believe and hope that together we will end it in an even more favorable position.

For further information, please contact:
Göran Beijer, CEO
Tel: +46 (0) 706 63 60 09

Jessica Roxhed, CFO
Tel: +46 70-394 94 98

About Dicot AB                                               

Dicot is developing the drug candidate LIB-01 (formerly Libiguin), which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion.

Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 1,800 shareholders. For more information, please visit

Dicot tecknar utvecklingsavtal med ledande leverantörer inom formulering

Pressmeddelande: Uppsala, 8 juni 2021. Dicot förbereder sig för de inledande kliniska studierna på människa. Sättet som företagets läkemedelskandidat tillförs försökspersonerna, dvs dess formulering, är av största betydelse för de här studierna. Därför har avtal tecknats med två ledande bolag inom formuleringsutveckling.

Dicot signs development agreements with leading suppliers in formulation

Press release: Uppsala, June 8, 2021. Dicot is preparing for the initial human clinical trials. The way in which the company's drug candidate is administered to the subjects, so-called formulation, is of the greatest importance for the studies. Therefore, agreements have been signed with two leading companies in formulation development.

Dicot rekryterar Chief Operating Officer

Pressmeddelande: Uppsala, 2 juni 2021. Dicot meddelar idag att företaget anställt Elin Trampe som Chief Operating Officer tillika vice VD. Hon tillträder sin tjänst 1 september och kommer ingå i Dicots ledningsgrupp.

Erfaren läkemedelsutvecklare till Dicots styrelse

Pressmeddelande: Uppsala, 27 maj 2021. På Dicots årsstämma 25 maj valdes Per-Göran Gillberg, med 35 års erfarenhet från farmakologi, in som ordinarie styrelsemedlem.

Dicot AB delårsrapport januari - mars 2021

Pressmeddelande: Uppsala, 17 maj 2021. Dicot ABs (publ) delårsrapport för januari - mars 2021 finns nu tillgänglig på bolagets hemsida

Summary of Interim Report January - March 2021, Dicot AB

Press release: Uppsala, May 17, 2021. A summary of the Interim report January - March 2021, for Dicot AB (publ) is now avalible on the company webbsite 

Dicot AB årsredovisning för 2020

Pressmeddelande: Uppsala, 4 maj 2021. Dicot AB (publ) meddelar idag att bolagets årsredovisning för 2020 nu finns tillgänglig på bolagets hemsida,

Kallelse till årsstämma i Dicot AB (publ)

Aktieägarna i Dicot AB (publ), 559006-3490 ("Bolaget"), kallas härmed till årsstämma tisdagen den 25 maj 2021. Mot bakgrund av risken för spridning av Covid-19 och myndigheternas föreskrifter/råd om undvikande av sammankomster har styrelsen beslutat att bolagsstämman ska genomföras utan fysisk närvaro genom att aktieägare utövar sin rösträtt endast genom poströstning. Någon fysisk sammankomst kommer således inte att hållas.

Dicot tillförs 17,4 MSEK genom utnyttjande av teckningsoptioner av serie TO2

Pressmeddelande: Uppsala, 6 april 2021. Dicot AB (publ) ("Dicot" eller "Bolaget") meddelar utfallet från utnyttjandet av teckningsoptioner av serie TO2. Innehavare av teckningsoptioner av serie TO2 utnyttjade 21 163 347 teckningsoptioner, motsvarande cirka 97,02 procent av antalet utestående teckningsoptioner av serie TO2, för teckning av 21 163 347 aktier till teckningskursen 0,82 SEK per aktie. Genom utnyttjandet av teckningsoptionerna tillförs Dicot cirka 17,4 MSEK före emissionskostnader.

Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
SE-102 45 Stockholm, Sweden

08-692 21 90

Om beQuoted